Therapeutic Area | MeSH |
---|---|
urogenital diseases | D000091642 |
signs and symptoms pathological conditions | D013568 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MYRBETRIQ | Astellas Pharma | N-202611 RX | 2012-06-28 | 2 products, RLD, RS |
MYRBETRIQ GRANULES | Astellas Pharma | N-213801 RX | 2021-03-25 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
mirabegron | ANDA | 2025-03-07 |
myrbetriq | New Drug Application | 2025-03-13 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
overactive urinary bladder | EFO_1000781 | D053201 | N32.81 |
urge urinary incontinence | EFO_0006865 | D053202 | N39.41 |
Expiration | Code | ||
---|---|---|---|
MIRABEGRON, MYRBETRIQ, APGDI | |||
2024-09-25 | PED | ||
2024-03-25 | I-855 | ||
MIRABEGRON, MYRBETRIQ GRANULES, APGDI | |||
2024-09-25 | PED | ||
2024-03-25 | NP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 4 | 5 | 14 | 9 | 5 | 36 |
Healthy volunteers/patients | — | — | — | 22 | — | — | 2 | — | 24 |
Urge urinary incontinence | D053202 | EFO_0006865 | N39.41 | — | — | 2 | 1 | 1 | 4 |
Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | — | — | 2 | — | 2 |
Lower urinary tract symptoms | D059411 | EFO_0008008 | — | — | 1 | — | 1 | — | 2 |
Interstitial cystitis | D018856 | EFO_1000869 | N30.1 | — | — | 1 | 1 | — | 2 |
Hyperplasia | D006965 | EFO_0000536 | — | — | — | — | 1 | — | 1 |
Hypertrophy | D006984 | EFO_0002460 | — | — | — | — | 1 | — | 1 |
Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | 1 | — | 1 |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Urologic diseases | D014570 | — | N39.9 | — | 1 | 4 | — | 1 | 6 |
Urinary bladder diseases | D001745 | — | N32.9 | — | 1 | 4 | — | 1 | 6 |
Cystitis | D003556 | EFO_1000025 | N30 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Wounds and injuries | D014947 | — | T14.8 | 1 | 2 | — | — | — | 3 |
Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | 2 | — | — | — | 3 |
Neoplasms | D009369 | — | C80 | — | 1 | — | — | 1 | 2 |
Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 1 | 2 | — | — | — | 2 |
Thermogenesis | D022722 | — | — | 2 | 2 | — | — | — | 2 |
Myeloproliferative disorders | D009196 | — | D47.1 | — | 1 | — | — | — | 1 |
Essential thrombocythemia | D013920 | — | D47.3 | — | 1 | — | — | — | 1 |
Polycythemia vera | D011087 | — | D45 | — | 1 | — | — | — | 1 |
Primary myelofibrosis | D055728 | — | D47.4 | — | 1 | — | — | — | 1 |
Thrombocytosis | D013922 | — | D75.83 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pharmacokinetics | D010599 | — | — | 6 | — | — | — | — | 6 |
Biological availability | D001682 | — | — | 2 | — | — | — | — | 2 |
Drug interactions | D004347 | — | — | 2 | — | — | — | — | 2 |
Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 1 | — | — | — | — | 1 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 1 | — | — | — | — | 1 |
Esophageal achalasia | D004931 | — | K22.0 | 1 | — | — | — | — | 1 |
Metabolism | D008660 | GO_0008152 | — | 1 | — | — | — | — | 1 |
Disease | D004194 | EFO_0000408 | R69 | 1 | — | — | — | — | 1 |
Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
Intraocular pressure | D007429 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 2 | 2 |
Sexual behavior | D012725 | — | — | — | — | — | — | 1 | 1 |
Behavior therapy | D001521 | — | — | — | — | — | — | 1 | 1 |
Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
Nocturnal enuresis | D053206 | — | N39.44 | — | — | — | — | 1 | 1 |
Deprescriptions | D000069340 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Mirabegron |
INN | mirabegron |
Description | Mirabegron is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2-amino-1,3-thiazol-4-ylacetic acid with the anilino group of (1R)-2-{[2-(4-aminophenyl)ethyl]amino}-1-phenylethanol. Used for the treatment of overactive bladder syndrome. It has a role as a beta-adrenergic agonist. It is a member of 1,3-thiazoles, an aromatic amide, a member of ethanolamines and a monocarboxylic acid amide. |
Classification | Small molecule |
Drug class | beta3 adrenoreceptor agonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1 |
PDB | — |
CAS-ID | 223673-61-8 |
RxCUI | — |
ChEMBL ID | CHEMBL2095212 |
ChEBI ID | 65349 |
PubChem CID | 9865528 |
DrugBank | DB08893 |
UNII ID | MVR3JL3B2V (ChemIDplus, GSRS) |